Specifications
- Tipo anticorpo:Primary
- Tipo di anticorpi:Epidermal growth factor receptor
- Simbolo dell'antigene:EGFR
- Clonalità:Policlonale
- Coniugazione:Non coniugato
- Ospite:Rabbit
- Isotipo:IgG
- Reattività:Human
- Western blot:Yes
- Assorbimento incrociato:none
- ID gene:1956
- Sinomini antigene:PIG61|HER1|mENA|ERBB|NISBD2|ERBB1
- Temperatura di conservazione:Store for 1 year at –20 °C from date of shipment
- Temperatura di spedizione:Ice
- Immunogeno:Synthetic peptide
- Taglia:100 µl
- Conf:0,1 mL
Specifications
About this item
The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase of the ErbB (also known as HER) family in which four members have been identified: EGFR (ErbB1), HER2/Neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). All four erbB receptors are composed of an extracellular ligand-binding region consisting of glycosylated domains, a transmembrane domain containing a single hydrophobic anchor sequence, an intracellular region containing the catalytic tyrosine kinase domain, and a carboxyl-terminal region containing several tyrosine residues that become phosphorylated after receptor activation.
The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important pathways that regulate growth, survival, proliferation, and differentiation in mammalian cells. EGFR and other members of the erbB family form either homodimers or heterodimers upon ligand binding, resulting in conformational changes that allow activation of protein kinases and transphosphorylation of key tyrosine residues within the carboxyl-terminal domain. After the induction of tyrosine phosphorylation, some signaling pathways appear to start with the recognition of the C-terminal phosphotyrosines by appropriate adaptor or signaling molecules. The aberrant activation of the EGFR leads to enhanced proliferation and other tumor-promoting activities. Several mechanisms lead to aberrant receptor activation, including receptor overexpression, gene amplification, activating mutations, overexpression of receptor ligands, and/or loss of their negative regulatory mechanisms.
The epidermal growth factor receptor (EGFR) has been extensively investigated as a target for anti-neoplastic therapy. Anti-EGFR antibodies that interfere with ligand-dependent receptor activation have shown clinical activity in a variety of solid tumors.
Western Blot: 1:2000;
Type: Primary
Antigen: EGFR/ERBB2 (epidermal growth factor receptor/v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2)
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human